First oral treatment for bad cholesterol approved
The U.S. Food and Drug Administration (FDA) has approved Livfendra (inclisiran) as the first oral medication used to inhibit the PCSK9 protein. It aims to lower low-density lipoprotein (LDL) cholesterol levels in adults, particularly those with familial hypercholesterolemia and individuals who have not responded adequately to traditional treatments like statins. The medication is taken once daily in tablet form, offering patients a more convenient option compared to previous injectable therapies, which required periodic injections and were more expensive. Studies show that the drug reduces LDL cholesterol by approximately 56-59% over 24 weeks, with mild side effects such as diarrhea and dizziness. The choice between the oral medication and injections depends on the patient's condition and compliance, with an expectation of更多 oral formulations becoming available in the future thanks to modern technologies.
Notice: This Is an AI-Generated Summary
Comments (0)